Policy ForumMedicine

Clinical Trials and Industry

Science  27 Sep 2002:
Vol. 297, Issue 5590, pp. 2211
DOI: 10.1126/science.1074543

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

Several disputes between clinical researchers and pharmaceutical manufacturers have highlighted the critical importance of protecting the right of trial subjects to disclosure of risks and the academic freedom of investigators. In this Policy Forum, some lessons from an inquiry into the case involving Dr. Nancy Olivieri, Apotex Inc., the Hospital for Sick Children, and the University of Toronto are outlined. Given that pharmaceutical companies are more powerful than individual researchers, it is essential that institutions live up to their responsibilities to protect the public interest by ensuring they have robust policies and practices in place governing disclosure of risks and academic independence.

Related Content